Furthermore, to increase the efficacy of immunotherapy for TNBC, the introduction of the B7‐H3‐CD3 bispecific antibody allowed the assessment of whether the combination of ICAM‐1–Dxd with B7‐H3‐CD3 could reprogram the TIM to reverse the tumor immune “cold” phenotype into the “hot” inflammatory phenotype. The gene discussed is ICAM1; the disease is neoplasm.